Good morning, everyone. Today's lecture focuses on the experimental challenges associated with CRISPR-Cas9 gene editing, despite its revolutionary potential. While CRISPR offers unprecedented precision in targeting specific DNA sequences, several hurdles remain.  Off-target effects, where the Cas9 enzyme inadvertently modifies unintended genomic locations, represent a significant concern, demanding rigorous screening methods like whole-genome sequencing to assess unintended mutations.  Furthermore, efficient delivery of the CRISPR-Cas9 system to target cells poses a challenge, particularly in vivo. Viral vectors, while effective, can trigger immune responses.  Non-viral delivery methods, such as lipid nanoparticles, often exhibit lower transfection efficiencies.  Finally, the complexity of gene regulation necessitates careful consideration.  Simply altering a single gene might have unforeseen downstream consequences, requiring extensive phenotypic analysis to fully understand the effects of gene editing.  Overcoming these challenges remains crucial for the safe and effective translation of CRISPR technology into therapeutic applications.